Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Clermont Ferrand – page 31

651 clinical trials in Clermont Ferrand, France across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Clermont Ferrand at a glance
651
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

651 trials in Clermont Ferrand

Open in trial search

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Smoking cessation therapy

Not yet recruiting

Study on Using Nicotine Electronic Cigarettes and Varenicline for Smoking Cessation in Smokers of 10+ Cigarettes Daily

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Varenicline
  • Sponsor:Assistance Publique Hopitaux De Paris

Plasma cell myeloma

Not yet recruiting

Study of ixazomib, iberdomide and dexamethasone combination in elderly patients with first relapse of multiple myeloma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Dexamethasone
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Implantation complication

Not yet recruiting

Study on Certolizumab for Women with Unexplained Recurrent Implantation Failure

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Certolizumab Pegol
  • Sponsor:Assistance Publique Hopitaux De Paris

Ductal adenocarcinoma of pancreas

Not yet recruiting

Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Association Gercor

Plasma cell myeloma

Not yet recruiting

Study on Multiple Myeloma Treatment with Isatuximab, Lenalidomide, and Carfilzomib for Patients Under 66 Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Carfilzomib
  • Sponsor:Intergroupe Francophone Du Myelome

Granulomatosis with polyangiitis

Not yet recruiting

Study on Rituximab, Tocilizumab, and Tofacitinib for Patients with Granulomatosis with Polyangiitis Not Responding to Standard Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Endometrial cancer

Not yet recruiting

Study Comparing Chemotherapy Alone to Dostarlimab, Paclitaxel, and Carboplatin for Patients with Advanced or Metastatic Endometrial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Carboplatin
  • Sponsor:Arcagy Gineco

Nervous system disorder

Not yet recruiting

Continued Access Study for Patients with Neurological Disease Using Ocrelizumab and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Cervix carcinoma+2

Not yet recruiting

Study on the Effectiveness of Carboplatin and Paclitaxel in Treating Cervical Cancer with Para-aortic Lymph Node Involvement

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Skin squamous cell carcinoma metastatic+1

Not yet recruiting

Study of INCB099280 for Patients With Advanced Cutaneous Squamous Cell Carcinoma Not Suitable for Surgery or Radiotherapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Incb099280
  • Sponsor:Incyte Corp.

Colitis ulcerative

Not yet recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Clermont Ferrand

What the registry says about research in the country

01 Gastrointestinal Research

Innovative studies focusing on inflammatory bowel diseases including groundbreaking trials examining fecal microbiota transplantation in both Crohn's disease and ulcerative colitis. Research aims to evaluate new therapeutic approaches for patients with moderate to severe conditions.

  • Crohn's Disease Management
  • Ulcerative Colitis Treatment
  • Microbiota-based Therapies

These trials are exploring alternative treatment pathways for patients who have not responded to conventional therapies.

02 Oncology Studies

Comprehensive research in multiple myeloma and various cancer types, including innovative treatments for esophageal squamous cell carcinoma and pleural mesothelioma. Studies evaluate new therapeutic combinations and maintenance strategies.

  • Blood Cancer Treatments
  • Prostate Cancer Therapy
  • Biliary Tract Cancer Research

Focus on improving patient outcomes through targeted therapies and immunological approaches.

03 Autoimmune Conditions

Advanced research into rheumatoid arthritis and multiple sclerosis, investigating optimized treatment protocols and maintenance therapies. Studies aim to improve long-term disease management and patient quality of life.

  • Multiple Sclerosis Treatments
  • Rituximab Optimization
  • Antibody-based Therapies

Emphasis on developing more effective and tolerable treatment regimens.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.